tbuckley/cabot-search huggingface dataset:
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis
Authors: Ran Weissman, Eli L. Diamond, Julien Haroche, Benjamin H. Durham, Fleur Cohen, Justin Buthorn, Zahir Amoura, Jean-François Emile, Roei D. Mazor, Noam Shomron, Omar I. Abdel-Wahab, Ofer Shpilberg, Oshrat Hershkovitz-Rokah
Journal: Leukemia (2021)

Erdheim-Chester disease (ECD) is characterized by excessive production and accumulation of histiocytes within multiple tissues and organs. ECD patients harbor recurrent mutations of genes associated with the RAS/RAF/MEK/ERK signaling pathway, particularly, the BRAFV600E mutation. Following our previous finding that miR-15a-5p is the most prominently downregulated microRNA in ECD patients compared to healthy individuals, we elucidated its role in ECD pathogenesis. Bioinformatics analysis followed by a luciferase assay showed that chemokine ligand 10 (CXCL10) is a target gene regulated by miRNA-15a-5p. This was confirmed in 24/34 ECD patients that had low expression of miR-15a-5p concurrent with upregulated CXCL10. Overexpression of miR-15a-5p in cell lines harboring BRAF or RAS mutations (Ba/F3, KG-1a and OCI-AML3) resulted in CXCL10 downregulation, followed by LIN28a and p-ERK signaling downregulation and let-7 family upregulation. Overexpression of miR-15a-5p inhibited cell growth and induced apoptosis by decreasing Bcl-2 and Bcl-xl levels. Analysis of sequential samples from 7 ECD patients treated with MAPK inhibitors (vemurafenib/cobimetinib) for 4 months showed miR-15a-5p upregulation and CXCL10 downregulation. Our findings suggest that miR-15a-5p is a tumor suppressor in ECD through the CXCL10-ERK-LIN28a-let7 axis, highlighting another layer of post-transcriptional regulation in this disease. Upregulation of miR-15a-5p in ECD patients may have a potential therapeutic role.
Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
Authors: David Wirta, Patrick Vollmer, James Paauw, Kuei-Hsun Chiu, Eugenia Henry, Kristen Striffler, Jeffrey Nau, David Wirta, Jay Rubin, Charles Reilly, Lance Bergstrom, Karl Olsen, Gary Jerkins, Guruprasad Pattar, Bruce Segal, Carol Aune, John Goosey, Joel Geffin, Daniel Terveen, Kenneth Kenyon, Jung Dao, Kenneth Kenyon, Jared Peterson, Daniel Zimmer, Patrick Vollmer, Blair Boehmer, James Paauw, Yen Nieman, Eva Liang
Journal: Ophthalmology (2021)

To evaluate the efficacy and safety of OC-01 (varenicline solution) nasal spray for treatment of patients with dry eye disease.Randomized, multicenter, double-masked, vehicle-controlled, phase 3 study.Adults 22 years of age or older with a diagnosis of dry eye disease, artificial tear use, Ocular Surface Disease Index score of 23 or more, and Schirmer test score (STS) of 10 mm or less. Eligibility was not restricted by eye dryness score (EDS).Patients (N = 758) were randomized in a 1:1:1 ratio to twice-daily treatment with 50-μl intranasal spray in each nostril of OC-01 0.03 mg (n = 260), OC-01 0.06 mg (n = 246), or vehicle (control; n = 252) for 4 weeks (ClinicalTrials.gov identifier, NCT04036292).The primary efficacy end point was the percentage of patients achieving a 10-mm improvement or more in STS at week 4. Secondary end points included change from baseline to week 4 in STS and EDS in a controlled adverse environment (CAE) chamber and in the clinic. Treatment-emergent adverse events (TEAEs) were assessed.A statistically significantly greater percentage of patients achieved the primary end point in both OC-01 treatment groups compared with the vehicle group (OC-01 0.03 mg, 47.3%; OC-01 0.06 mg, 49.2%; vehicle, 27.8%; P < 0.0001 for both doses). Change from baseline in STS at week 4 was statistically significantly greater for patients receiving OC-01 than vehicle (P < 0.0001 for both doses). Eye dryness score assessed at week 4 improved with OC-01 treatment compared with vehicle, although the difference was not significant for EDS measured in the CAE chamber and showed (nominal) significance in the clinic. Overall, 86.5% of patients (654/756) reported at least 1 TEAE during the treatment period; most were mild, nonocular (sneezing, cough, throat irritation, and instillation site irritation) and were reported by fewer patients in the vehicle group than in the OC-01 treatment groups (OC-01 0.03 mg, 97.3%; OC-01 0.06 mg, 99.2%; vehicle, 57%).OC-01 nasal spray was well tolerated and showed a clinically meaningful effect on signs and symptoms of dry eye disease.
Erythematous Papules and Hemorrhagic Vesicles in a Woman With Arthralgias and Eye Pain
Authors: Lindsey West, Sung Kyung Cho, Cristina Thomas
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma
Authors: Anita Kumar, Jason R. Westin, Stephen J. Schuster, Grzegorz S. Nowakowski, Izidore S. Lossos, Devin Copley, Clare Grieve, Allison P. Jacob, Ashlee Joseph, Leana Laraque, Gita Masand, Chelsea D Mullins, Ellen Napier, Tania Rodriguez, Venkatraman Seshan, Shreya Vemuri, Andrew D. Zelenetz
Journal: Blood (2021)
Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in <i>TCF3-Hlf</i> B-ALL
Authors: Asen Bagashev, Joseph Patrick Loftus, Colin Wakefield, Gerald Wertheim, Christian Hurtz, Martin P. Carroll, Kimberly Stegmaier, Yana Pikman, Sarah K Tasian
Journal: Blood (2021)
Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90
Authors: Kebede H. Begna, Naseema Gangat, Mithun V. Shah, Hassan B. Alkhateeb, Mrinal M. Patnaik, Aref Al-Kali, Michelle A. Elliot, William J Hogan, Mark R. Litzow, C. Christopher Hook, Abhishek A. Mangaonkar, David S Viswanatha, Dong Chen, Animesh D. Pardanani, Rhett P. Ketterling, Ayalew Tefferi
Journal: Blood (2021)
Spatial Transcriptomics Reveals DPP4 As Novel Marker of a More Proliferative Phenotype in Early AML Progression
Authors: Christa Haase, Karin Gustafsson, Shenglin Mei, Jelena Milosevic, Shu-Chi Yeh, David Sykes, Peter Kharchenko, David T. Scadden, Charles Lin
Journal: Blood (2021)
A Focus on Phenotype and Genotype: Racial /Ethnic Disparities in Myelodysplastic Syndromes
Authors: Sara Marie Tinsley-Vance, Najla Al Ali, Somedeb Ball, Akriti G Jain, Luis E. E. Aguirre, David Kaldas, Onyee Chan, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Andrew T. Kuykendall, David A. Sallman, Rami S. Komrokji
Journal: Blood (2021)
A novel cytokine consisting of the p40 and EBI3 subunits suppresses experimental autoimmune arthritis via reciprocal regulation of Th17 and Treg cells
Authors: Seon-Yeong Lee, Su-Jin Moon, Young-Mee Moon, Hyeon-Beom Seo, Jun-Geol Ryu, A Ram Lee, Chae Rim Lee, Da-Som Kim, Yang-Mi Her, Jeong Won Choi, Seung-Ki Kwok, Sung-Hwan Park, Mi-La Cho
Journal: Cellular and Molecular Immunology (2021)

Abstract Objective The interleukin (IL)-12 cytokine family is closely related to the development of T helper cells, which are responsible for autoimmune disease enhancement or suppression. IL-12 family members are generally heterodimers and share three α-subunits (p35, p19, and p28) and two β-subunits (p40 and EBI3). However, a β-sheet p40 homodimer has been shown to exist and antagonize IL-12 and IL-23 signaling 1 . Therefore, we assumed the existence of a p40-EBI3 heterodimer in nature and sought to investigate its role in immune regulation. Methods The presence of the p40-EBI3 heterodimer was confirmed by ELISA, immunoprecipitation, and western blotting. A p40-EBI3 vector and p40-EBI3-Fc protein were synthesized to confirm the immunological role of this protein in mice with collagen-induced arthritis (CIA). The anti-inflammatory effects of p40-EBI3 were analyzed with regard to clinical, histological, and immune cell-regulating features in mice with CIA. Results Clinical arthritis scores and the expression levels of proinflammatory cytokines (e.g., IL-17, IL-1β, IL-6, and TNF-α) were significantly attenuated in p40-EBI3-overexpressing and p40-EBI3-Fc-treated mice with CIA compared to vehicle-treated mice with CIA. Structural joint damage and vessel formation-related gene expression were also reduced by p40-EBI3 heterodimer treatment. In vitro, the p40-EBI3-Fc protein significantly suppressed the differentiation of Th17 cells and reciprocally induced CD4 + CD25 + Foxp3 + (regulatory T) cells. p40-EBI3 also inhibited osteoclast formation in a concentration-dependent manner. Conclusion In this study, p40-EBI3 ameliorated proinflammatory conditions both in vivo and in vitro. We propose that p40-EBI3 is a novel anti-inflammatory cytokine involved in suppressing the immune response through the expansion of Treg cells and suppression of Th17 cells and osteoclastogenesis.
Association between Neighborhood Disadvantage and Health Status/Healthcare Utilization in Survivors of Blood or Marrow Transplantation (BMT) - a BMTSS Report
Authors: Julie A. Wolfson, Smita Bhatia, Lindsey Hageman, Elizabeth Schlichting, Nora Balas, Liton F. Francisco, Erin Funk, Jessica Hicks, Wendy Landier, Arianna Siler, Alysia Bosworth, Saro H. Armenian, Mukta Arora, Hok Sreng Te, Monica A. Aswani, Jessica Wu
Journal: Blood (2021)
Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy
Authors: Joanna C. Zurko, Narendranath Epperla, Imran Nizamuddin, Pallawi Torka, Kevin A. David, Thomas A. Ollila, Brian T. Hess, Jonathon B. Cohen, Robert Ferdman, Jieqi Liu, Sayan Mullick Chowdhury, Kaitlyn O'Shea, Jason Romancik, Rahul Bhansali, Elyse Harris, Mckenzie Sorrell, Rebecca Masel, Lindsey Fitzgerald, Carlos Galvez, Shuo Ma, Jane N. Winter, Barbara Pro, Leo I. Gordon, Alexey V. Danilov, Deborah M. Stephens, Nirav N. Shah, Geoffrey Shouse, Vaishalee P. Kenkre, Stefan K. Barta, Reem Karmali
Journal: Blood (2021)
Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
Authors: Amandine Le Bourgeois, Marianne Coste-Burel, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Berthe-Marie Imbert, Thomas Drumel, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Anne Lok, Cyrille Touzeau, Thomas Gastinne, Benoit Tessoulin, Maxime Jullien, Sophie Vantyghem, Marie C Bene, Philippe Moreau, Steven Le Gouill, Patrice Chevallier
Journal: Blood (2021)
Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial
Authors: Rachel A. Warren, Allie S. Carew, Pantelis Andreou, Christine Herman, Andrew P. Levy, Henry N. Ginsberg, John Sapp, Eric B. Rimm, Susan Kirkland, Leah E. Cahill
Journal: Diabetes Care (2021)

The haptoglobin (Hp)2-2 phenotype (∼35-40% of people) is associated with increased oxidation and dysfunctional HDL in hyperglycemia and may explain why drugs designed to pharmacologically raise HDL cholesterol and lower triglycerides have not reliably prevented cardiovascular disease in diabetes. We aimed to determine whether the effect of adding fenofibrate versus placebo to simvastatin on the risk of coronary artery disease (CAD) events depends on Hp phenotype in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial.Cox proportional hazards regression models quantified the relationship between fenofibrate therapy and CAD events in the ACCORD lipid trial in participants with the Hp2-2 phenotype (n = 1,795) separately from those without (n = 3,201).Fenofibrate therapy successfully lowered the risk of CAD events in participants without the Hp2-2 phenotype (multivariable adjusted hazard ratio 0.74 [95% CI 0.60-0.90] compared with no fenofibrate therapy) but not in participants with the Hp2-2 phenotype (1.16 [0.87-1.56]; P interaction = 0.009). Subgroup analyses revealed that this protective effect of fenofibrate against CAD events among the non-Hp2-2 phenotype group was pronounced in participants with severe dyslipidemia (P interaction = 0.01) and in males (P interaction = 0.02) with an increased CAD risk from fenofibrate treatment observed in females with the Hp2-2 phenotype (P interaction = 0.002).The effect of fenofibrate added to simvastatin on risk of CAD events depends on Hp phenotype in the ACCORD lipid trial.
<i>PIEZO1</i> Mutation May Determine Early Onset of Clinical Manifestation of Anemia of Myelodysplastic Syndromes
Authors: Enrico Attardi, Immacolata Andolfo, Lucia Tiberi, Roberta Russo, Daniela Formicola, Alice Brogi, Marco Gabriele Raddi, Angela Consagra, Cristina Amato, Alessandro Sanna, Rosangela Artuso, Achille Iolascon, Valeria Santini
Journal: Blood (2021)
Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors
Authors: Sanghee Hong, Jing Zhao, Ji-Hyun Lee, Nosha Farhadfar, Jean C. Yi, Jaime M. Preussler, K. Scott Baker, Bronwen E. Shaw, Steven Devine, Karen Syrjala, John R. Wingard, Navneet S. Majhail, Zeina Al-Mansour
Journal: Blood (2021)
Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study
Authors: Mariana Bastos-Oreiro, Antonio Gutierrez, Juan Luis Reguera, Gloria Iacoboni, Lucía López Corral, María José Terol, Valentín Ortiz-Maldonado, Jaime Sanz, Luisa Maria Guerra, Alberto Mussetti, Pau Abrisqueta Costa, Javier Delgado Serrano, Rafael Hernani, Hugo Daniel Luzardo Henriquez, Juan-Manuel Sancho, Carlos Montalban, Antonio Salar, Carlos Grande, Leyre Bento, Sonia González de Villambrosia, Daniel Garcia, Blanca Herrero, Nuria Martínez-Cibrian, Anna Sureda, Antonio Perez-Martinez, Pere Barba, Mi Kwon, Alejandro Martin Garcia-Sancho
Journal: Blood (2021)
Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation
Authors: Julie Bruce, Bruno Mazuquin, Alastair Canaway, Anower Hossain, Esther Williamson, Pankaj Mistry, Ranjit Lall, Stavros Petrou, Sarah E Lamb, Sophie Rees, Emma Padfield, Raghavan Vidya, Alastair M Thompson
Journal: BMJ (2021)

Abstract Objective To evaluate whether a structured exercise programme improved functional and health related quality of life outcomes compared with usual care for women at high risk of upper limb disability after breast cancer surgery. Design Multicentre, pragmatic, superiority, randomised controlled trial with economic evaluation. Setting 17 UK National Health Service cancer centres. Participants 392 women undergoing breast cancer surgery, at risk of postoperative upper limb morbidity, randomised (1:1) to usual care with structured exercise (n=196) or usual care alone (n=196). Interventions Usual care (information leaflets) only or usual care plus a physiotherapy led exercise programme, incorporating stretching, strengthening, physical activity, and behavioural change techniques to support adherence to exercise, introduced at 7-10 days postoperatively, with two further appointments at one and three months. Main outcome measures Disability of Arm, Hand and Shoulder (DASH) questionnaire at 12 months, analysed by intention to treat. Secondary outcomes included DASH subscales, pain, complications, health related quality of life, and resource use, from a health and personal social services perspective. Results Between 26 January 2016 and 31 July 2017, 951 patients were screened and 392 (mean age 58.1 years) were randomly allocated, with 382 (97%) eligible for intention to treat analysis. 181 (95%) of 191 participants allocated to exercise attended at least one appointment. Upper limb function improved after exercise compared with usual care (mean DASH 16.3 (SD 17.6) for exercise (n=132); 23.7 (22.9) usual care (n=138); adjusted mean difference 7.81, 95% confidence interval 3.17 to 12.44; P=0.001). Secondary outcomes favoured exercise over usual care, with lower pain intensity at 12 months (adjusted mean difference on numerical rating scale −0.68, −1.23 to −0.12; P=0.02) and fewer arm disability symptoms at 12 months (adjusted mean difference on Functional Assessment of Cancer Therapy-Breast+4 (FACT-B+4) −2.02, −3.11 to −0.93; P=0.001). No increase in complications, lymphoedema, or adverse events was noted in participants allocated to exercise. Exercise accrued lower costs per patient (on average −£387 (€457; $533) (95% confidence interval −£2491 to £1718; 2015 pricing) and was cost effective compared with usual care. Conclusions The PROSPER exercise programme was clinically effective and cost effective and reduced upper limb disability one year after breast cancer treatment in patients at risk of treatment related postoperative complications. Trial registration ISRCTN Registry ISRCTN35358984 .
Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age
Authors: Darcy R. Flora, Susan K. Parsons, Nicholas Liu, Kristina S. Yu, Katie Holmes, Carlos Flores, Michelle A. Fanale, Supriya Kumar, Andy Surinach, Rachel Byrd, Andrew M. Evens
Journal: Blood (2021)
Author’s response to Z. Huang on his commentary on “Effect of a perioperative immune-enhancing diet in clean-contaminated head and neck cancer surgery: A randomized controlled trial” (Int. J. Surg. 94 (2021) 106114)
Authors: Pichit Sittitrai, Donyarat Ruenmarkkaew, Somkamol Booyaprapa, Boonsita Kasempitakpong
Journal: International Journal of Surgery (2021)
The First Results of Asciminib Therapy in Highly Pretreated Chronic Myeloid Leukemia Patients Under the Managed Access Program (MAP) in Russian Federation
Authors: Anna G. Turkina, Oleg A. Shukhov, Elza Lomaia, Elena V. Morozova, Anna Petrova, Ekaterina Yu. Chelysheva, Tamara Chitanava, Julia J. Vlasova, Irina Nemchenko, Anastasiya Bykova, Margarita Gurianova, Andrey Zaritsky
Journal: Blood (2021)
Disparities in “Difficult Relationships” Between Clinicians and Parents of Children With Cancer
Authors: Kristine A. Karvonen, Abby R. Rosenberg
Journal: JAMA Network Open (2021)

Although difficult conversations are well-studied in pediatric oncology, difficult relationships are less understood.This is important because difficult relationships between patients, their caregivers, and clinicians are common, may break therapeutic alliances, and contribute to clinician burnout and family distress.What makes a parent-clinician relationship difficult?What is the parent's perspective?
Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era
Authors: Maria Queralt Salas, Luis Gerardo Rodríguez-Lobato, María Suárez-Lledó, Nuria Martínez-Cibrian, Teresa Solano, Jordi Arcarons, Noemí Llobet, Ariadna Domenech, Alexandra Pedraza, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Laura Rosinol, Francesc Fernández-Avilés, Gonzalo Gutiérrez-García, Enric Carreras, Jordi Esteve, Álvaro Urbano-Ispizua, Montserrat Rovira, Carmen Martínez
Journal: Blood (2021)
Genomic-Based Machine Learning Towards Prediction of the Etiology of Bone Marrow Failure Syndromes
Authors: Fernanda Gutierrez-Rodrigues, Eric Munger, Xiaoyang Ma, Youbao Tang, Emma M Groarke, Bhavisha A. Patel, Luiz Fernando Bazzo Catto, Diego V Clé, Marena R. Niewisch, Flávia S Donaires, Sachiko Kajigaya, Cynthia E. Dunbar, Neelam Giri, Michel Michels De Oliveira, Lisa J. McReynolds, Blanche P. Alter, Sharon A. Savage, Carmem M. S. Bonfim, Colin O. Wu, Rodrigo T. Calado, Neal S. Young
Journal: Blood (2021)
Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat
Authors: Sandeep S. Dave, Lanie Happ, Christopher Yasso, Gilles Salles, Connie Lee Batlevi, Tycel Phillips, Jay Yang, Deyaa Adib, Neil R. Michaud, Franck Morschhauser
Journal: Blood (2021)
TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy
Authors: William T. Johnson, Nivetha Ganesan, Zachary D. Epstein-Peterson, Catherine Maccaro, Natasha Galasso, Craig S. Sauter, Rachel Neuman, Niloufer Khan, Alison J. Moskowitz, Ahmet Dogan, Steven M. Horwitz
Journal: Blood (2021)
Tuberculosis and COVID-19 co-infection: description of the global cohort
Journal: European Respiratory Journal (2021)

Background Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes. Methods We enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (&gt;50% population-based). Results Of 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality. Conclusion The data suggest that TB and COVID-19 are a “cursed duet” and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.
Efficacy Outcomes of Isatuximab with Pomalidomide and Dexamethasone Are Comparable to (ICARIA-MM) Trial Data: Initial Results of a UK-Wide Real-World Study of Relapsed Myeloma Patients
Authors: Faouzi Djebbari, Grant Vallance, Nanda Basker, Fotios Panitsas, Alexandros Rampotas, Gina Sangha, Beena Salhan, Farheen Karim, Firas Al-kaisi, Amy Gudger, Loretta Ngu, Matt Poynton, Ho Pui Jeff Lam, Lowri Morgan, Laura Yang, Jennifer Young, Mairi Walker, Ismini Tsagkaraki, Laura Anderson, Saleena Rani Chauhan, Rebecca Maddams, Lesley Stirton, Margarita Triantafillou, Steve Prideaux, Abubaker Obeidalla, Ceri Bygrave, Supratik Basu, Karthik Ramasamy
Journal: Blood (2021)